Silverback Therapeutics Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Silverback Therapeutics's estimated annual revenue is currently $6M per year.
- Silverback Therapeutics's estimated revenue per employee is $155,000
- Silverback Therapeutics has 39 Employees.
- Silverback Therapeutics grew their employee count by 18% last year.
- Silverback Therapeutics currently has 1 job openings.
|Jill Herendeen||VP, Regulatory Affairs|
|Naomi Hunder||Senior Vice President, Clinical Research And Development|
|Graham Jang||Vice President, Development Sciences|
|Patti Leith||Vice President Program Management And Operations|
|Jeannette Bannink||Director of Bioanalytical|
|Valerie Odegard||Chief Scientific Officer|
|Peter Thompson||Co-Founder, President, CEO & Chairman|
|Patricia Leith||Executive Dir Program Management & Operations|
|Peter Baum||VP Immunology|
|Philip Tan||Executive Director, Protein Engineering|
What Is Silverback Therapeutics?
Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness ? until now. Our team brings together diverse perspectives and deep experience in drug discovery and development, allowing us to approach long-standing challenges in new ways. At the core of our pipeline is our proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administered to patients but that act only at the sites of disease, sparing healthy tissues from unwanted side effects. Armed with this technology, we believe that it is finally possible to overcome some of the biggest barriers to creating effective and enduring treatments for cancer, fibrosis, infectious diseases, and other devastating conditions. Silverback is based in the vibrant South Lake Union neighborhood in Seattle, Washington, where our multi-disciplinary team is rapidly advancing our lead programs toward clinical trials in multiple indications. Since our founding in 2016, we have raised $47.5 million in venture capital from OrbiMed, Celgene Corporation, and Alexandria Venture Investments.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Alpine Immune S...||$6.8M||56||19%||N/A|
|Global Medical ...||$6.7M||43||10%||N/A|